Priscilla Turelli (left) and Charlène Raclot analysing blood samples for...
Priscilla Turelli (left) and Charlène Raclot analysing blood samples for SARS-CoV-2 antibodies

© EPFL / Alain Herzog 2021

News • Covid-19 detection

New blood test measures immunity against SARS-CoV-2 and its variants

The Lausanne University Hospital (CHUV) and EPFL teamed up to develop a new test that’s sensitive enough to measure the amount of SARS-CoV-2 neutralizing antibodies present in the bloodstream.

The scientists’ discovery, published in Science Translational Medicine, opens promising new avenues for tracking immunity acquired by infection or vaccination. With this test, experts can measure the level of protection against variants of the virus and monitor their prevalence over time.

Blood tests detect the presence of antibodies against an infectious agent, such as SARS-CoV-2, in a patient’s bloodstream. Some antibodies simply indicate whether the individual has been previously exposed to either the virus or a vaccine, while others – known as neutralizing antibodies – provide immunity against infection or re-infection. In the case of SARS-CoV-2, neutralizing antibodies work by interfering with the virus’ spike protein, which is the key that the virus uses to enter respiratory system cells by binding to the ACE2 receptors on the cells’ surface. 

The research was carried out by the teams at the CHUV’s Service of Immunology and Allergy, which are led by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The new antibody test is a highly sensitive and extremely accurate way of measuring how well a sample of blood serum can prevent the spike protein in its trimeric form – as found on the surface of the SARS-CoV-2 virus – from binding to ACE2 receptors. It completes the diagnostic arsenal in development at EPFL, which also includes the microchip device presented two months ago. 

Because the new method requires a simple blood test, it can be deployed easily on a large scale. The test results show whether a patient has developed immunity against one or more variants of SARS-CoV-2. The research team was able to develop the test rapidly thanks to the core facilities set up and supported over many years by the Swiss Vaccine Research Institute. 

The new test is available at the CHUV’s Service of Immunology and Allergy, where it can be taken at the request of a doctor. The test costs CHF 100 and is not currently covered by Swiss health insurance plans.


Source: École Polytechnique Fédérale de Lausanne

16.07.2021

Read all latest stories

Related articles

Photo

News • Total antibody test

Siemens Healthineers to expand SARS-CoV-2 testing

Siemens Healthineers announced it is expanding its infectious disease testing capabilities to aid in the COVID-19 pandemic.

Photo

News • Blood sample

Paper test may predict Covid-19 immunity

The new test measures the level of neutralizing antibodies in a blood sample and could help people decide what protections they should take against infection.

Photo

News • Protein malformation

Covid-19: immune reaction may cause amyloid generation

In patients with serious and long-term Covid-19, disturbed blood coagulation is often observed. Now, Swedish researchers found a connection between harmful amyloid production and Covid-19 symptoms.

Related products

Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Mindray – CL-6000i Chemiluminescence Immunoassay System

Immunoassays

Mindray – CL-6000i Chemiluminescence Immunoassay System

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Mindray – CL-900i Chemiluminescence Immunoassay System

Immunoassays

Mindray – CL-900i Chemiluminescence Immunoassay System

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Subscribe to Newsletter